科兴制药
(688136)
| 流通市值：76.66亿 | | | 总市值：76.66亿 |
| 流通股本：2.00亿 | | | 总股本：2.00亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 353,559,464.74 | 1,406,925,448.3 | 1,038,255,976.88 | 759,894,679.84 |
| 营业收入 | 353,559,464.74 | 1,406,925,448.3 | 1,038,255,976.88 | 759,894,679.84 |
| 二、营业总成本 | 323,281,678.19 | 1,344,390,356.12 | 975,684,606.8 | 700,341,895.58 |
| 营业成本 | 113,578,376.51 | 440,527,341.44 | 312,948,824.45 | 217,468,332.38 |
| 税金及附加 | 3,223,738.23 | 12,229,811.75 | 8,901,107.96 | 6,355,011.38 |
| 销售费用 | 142,770,592.45 | 596,765,436.43 | 448,016,012.31 | 334,859,572.04 |
| 管理费用 | 19,244,051.06 | 85,962,747.7 | 61,220,949.1 | 42,224,597.43 |
| 研发费用 | 37,206,245.26 | 168,050,430.04 | 113,451,265.63 | 80,326,332.08 |
| 财务费用 | 7,258,674.68 | 40,854,588.76 | 31,146,447.35 | 19,108,050.27 |
| 其中:利息费用 | 10,452,112.31 | 43,571,269.16 | 32,550,819.66 | 21,241,223.83 |
| 其中:利息收入 | 722,885.78 | 3,626,754.45 | 3,087,391.72 | 2,112,233.05 |
| 加:公允价值变动收益 | - | -29,188,617.47 | -13,940,667.35 | -13,940,667.35 |
| 加:投资收益 | 3,803,273.11 | 9,325,939.69 | 5,822,896.4 | 4,084,588.18 |
| 资产处置收益 | 19,269.96 | 77,059.28 | 77,764.33 | 100,857.6 |
| 资产减值损失(新) | -429,850.07 | -3,669,050.48 | -3,044,547.36 | -2,187,250.09 |
| 信用减值损失(新) | -1,507,370.08 | -1,609,253.69 | -3,762,528.21 | -4,029,225.73 |
| 其他收益 | 1,954,838.54 | 25,729,346.04 | 8,003,815.38 | 4,184,274.51 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 34,117,948.01 | 63,200,515.55 | 55,728,103.27 | 47,765,361.38 |
| 加:营业外收入 | 6,503.06 | 197,345.11 | 130,348.17 | 130,827.97 |
| 减:营业外支出 | 2,338,951.16 | 6,495,252.51 | 5,967,941.14 | 5,916,583 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 31,785,499.91 | 56,902,608.15 | 49,890,510.3 | 41,979,606.35 |
| 减:所得税费用 | 6,934,393.15 | 29,854,052.75 | 36,141,019.29 | 32,518,139.69 |
| 六、净利润 | 24,851,106.76 | 27,048,555.4 | 13,749,491.01 | 9,461,466.66 |
| 持续经营净利润 | 24,851,106.76 | 27,048,555.4 | 13,749,491.01 | 9,461,466.66 |
| 归属于母公司股东的净利润 | 25,577,232.91 | 31,480,893.13 | 17,178,251.41 | 11,877,328.48 |
| 少数股东损益 | -726,126.15 | -4,432,337.73 | -3,428,760.4 | -2,415,861.82 |
| (一)基本每股收益 | 0.13 | 0.16 | 0.09 | 0.06 |
| (二)稀释每股收益 | 0.13 | 0.16 | 0.09 | 0.06 |
| 八、其他综合收益 | -3,532.56 | 1,119,696.97 | 357,532.77 | 345,384.48 |
| 归属于母公司股东的其他综合收益 | -3,532.56 | 1,119,696.97 | 357,532.77 | 345,384.48 |
| 九、综合收益总额 | 24,847,574.2 | 28,168,252.37 | 14,107,023.78 | 9,806,851.14 |
| 归属于母公司股东的综合收益总额 | 25,573,700.35 | 32,600,590.1 | 17,535,784.18 | 12,222,712.96 |
| 归属于少数股东的综合收益总额 | -726,126.15 | -4,432,337.73 | -3,428,760.4 | -2,415,861.82 |
| 公告日期 | 2025-04-28 | 2025-04-11 | 2024-10-26 | 2024-08-20 |
| 审计意见(境内) | | 标准无保留意见 | | |